Radiation-induced hepatic toxicity after radiotherapy combined with chemotherapy for hepatocellular carcinoma

Su J. Shim, Jinsil Seong, Ik J. Lee, KwangHyub Han, Chae Y. Chon, SangHoon Ahn

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Aim: The purpose of the present study was to analyze hepatic toxicity following radiotherapy combined with regional chemotherapy for hepatocellular carcinoma (HCC). Methods: From 2001 to 2003, a total of 132 patients with HCC received 3-D conformal radiation therapy (3D-CRT) combined with chemotherapy. Patients were divided into two groups based on drug localization: the transcatheter arterial chemoembolization (TACE) group, where the chemotherapeutic drug (adriamycin) was localized within the tumor, and the non-TACE group, where the drugs (adriamycin, cisplatin, 5-fluorouracil) were diffusely spread over the entire liver. Results: Patients were evaluated by biochemical parameters for any hepatic toxicity prior to, during, and until 12 months after 3D-CRT. Hepatic toxicity was defined as radiation-induced liver disease (RILD) or combined modality-induced liver disease (CMILD), which is defined as RILD with abnormal elevation of total bilirubin levels. In the TACE group, three patients developed RILD (5.6%) and none developed CMILD. In the non-TACE group, three patients (3.7%) and seven patients (8.8%) developed RILD and CMILD, respectively. Conclusion: Hepatic toxicity following radiotherapy combined with regional chemotherapy for HCC might be influenced by the distribution of the chemotherapeutic drugs. A more precise understanding of hepatic toxicity from chemoradiotherapy will help design optimal treatments for HCC.

Original languageEnglish
Pages (from-to)906-913
Number of pages8
JournalHepatology Research
Volume37
Issue number11
DOIs
Publication statusPublished - 2007 Nov 1

Fingerprint

Liver Diseases
Hepatocellular Carcinoma
Radiotherapy
Radiation
Drug Therapy
Liver
Pharmaceutical Preparations
Doxorubicin
Chemoradiotherapy
Bilirubin
Fluorouracil
Cisplatin
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Infectious Diseases

Cite this

@article{decf8d7614bb4fa0b5feec1983a066f1,
title = "Radiation-induced hepatic toxicity after radiotherapy combined with chemotherapy for hepatocellular carcinoma",
abstract = "Aim: The purpose of the present study was to analyze hepatic toxicity following radiotherapy combined with regional chemotherapy for hepatocellular carcinoma (HCC). Methods: From 2001 to 2003, a total of 132 patients with HCC received 3-D conformal radiation therapy (3D-CRT) combined with chemotherapy. Patients were divided into two groups based on drug localization: the transcatheter arterial chemoembolization (TACE) group, where the chemotherapeutic drug (adriamycin) was localized within the tumor, and the non-TACE group, where the drugs (adriamycin, cisplatin, 5-fluorouracil) were diffusely spread over the entire liver. Results: Patients were evaluated by biochemical parameters for any hepatic toxicity prior to, during, and until 12 months after 3D-CRT. Hepatic toxicity was defined as radiation-induced liver disease (RILD) or combined modality-induced liver disease (CMILD), which is defined as RILD with abnormal elevation of total bilirubin levels. In the TACE group, three patients developed RILD (5.6{\%}) and none developed CMILD. In the non-TACE group, three patients (3.7{\%}) and seven patients (8.8{\%}) developed RILD and CMILD, respectively. Conclusion: Hepatic toxicity following radiotherapy combined with regional chemotherapy for HCC might be influenced by the distribution of the chemotherapeutic drugs. A more precise understanding of hepatic toxicity from chemoradiotherapy will help design optimal treatments for HCC.",
author = "Shim, {Su J.} and Jinsil Seong and Lee, {Ik J.} and KwangHyub Han and Chon, {Chae Y.} and SangHoon Ahn",
year = "2007",
month = "11",
day = "1",
doi = "10.1111/j.1872-034X.2007.00149.x",
language = "English",
volume = "37",
pages = "906--913",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell",
number = "11",

}

Radiation-induced hepatic toxicity after radiotherapy combined with chemotherapy for hepatocellular carcinoma. / Shim, Su J.; Seong, Jinsil; Lee, Ik J.; Han, KwangHyub; Chon, Chae Y.; Ahn, SangHoon.

In: Hepatology Research, Vol. 37, No. 11, 01.11.2007, p. 906-913.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Radiation-induced hepatic toxicity after radiotherapy combined with chemotherapy for hepatocellular carcinoma

AU - Shim, Su J.

AU - Seong, Jinsil

AU - Lee, Ik J.

AU - Han, KwangHyub

AU - Chon, Chae Y.

AU - Ahn, SangHoon

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Aim: The purpose of the present study was to analyze hepatic toxicity following radiotherapy combined with regional chemotherapy for hepatocellular carcinoma (HCC). Methods: From 2001 to 2003, a total of 132 patients with HCC received 3-D conformal radiation therapy (3D-CRT) combined with chemotherapy. Patients were divided into two groups based on drug localization: the transcatheter arterial chemoembolization (TACE) group, where the chemotherapeutic drug (adriamycin) was localized within the tumor, and the non-TACE group, where the drugs (adriamycin, cisplatin, 5-fluorouracil) were diffusely spread over the entire liver. Results: Patients were evaluated by biochemical parameters for any hepatic toxicity prior to, during, and until 12 months after 3D-CRT. Hepatic toxicity was defined as radiation-induced liver disease (RILD) or combined modality-induced liver disease (CMILD), which is defined as RILD with abnormal elevation of total bilirubin levels. In the TACE group, three patients developed RILD (5.6%) and none developed CMILD. In the non-TACE group, three patients (3.7%) and seven patients (8.8%) developed RILD and CMILD, respectively. Conclusion: Hepatic toxicity following radiotherapy combined with regional chemotherapy for HCC might be influenced by the distribution of the chemotherapeutic drugs. A more precise understanding of hepatic toxicity from chemoradiotherapy will help design optimal treatments for HCC.

AB - Aim: The purpose of the present study was to analyze hepatic toxicity following radiotherapy combined with regional chemotherapy for hepatocellular carcinoma (HCC). Methods: From 2001 to 2003, a total of 132 patients with HCC received 3-D conformal radiation therapy (3D-CRT) combined with chemotherapy. Patients were divided into two groups based on drug localization: the transcatheter arterial chemoembolization (TACE) group, where the chemotherapeutic drug (adriamycin) was localized within the tumor, and the non-TACE group, where the drugs (adriamycin, cisplatin, 5-fluorouracil) were diffusely spread over the entire liver. Results: Patients were evaluated by biochemical parameters for any hepatic toxicity prior to, during, and until 12 months after 3D-CRT. Hepatic toxicity was defined as radiation-induced liver disease (RILD) or combined modality-induced liver disease (CMILD), which is defined as RILD with abnormal elevation of total bilirubin levels. In the TACE group, three patients developed RILD (5.6%) and none developed CMILD. In the non-TACE group, three patients (3.7%) and seven patients (8.8%) developed RILD and CMILD, respectively. Conclusion: Hepatic toxicity following radiotherapy combined with regional chemotherapy for HCC might be influenced by the distribution of the chemotherapeutic drugs. A more precise understanding of hepatic toxicity from chemoradiotherapy will help design optimal treatments for HCC.

UR - http://www.scopus.com/inward/record.url?scp=34548660373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548660373&partnerID=8YFLogxK

U2 - 10.1111/j.1872-034X.2007.00149.x

DO - 10.1111/j.1872-034X.2007.00149.x

M3 - Article

C2 - 17610506

AN - SCOPUS:34548660373

VL - 37

SP - 906

EP - 913

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 11

ER -